Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Option Care Health, Inc. (NasdaqGS: OPCH) to CD&R, McKesson Corporation, where shareholders are set to receive $32.05 in cash per share. KSF aims to determine if this consideration and the sale process are adequate or if the company is undervalued. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.
Shared voting power covers 8.67M shares in Wellington’s Option Care Health (OPCH) stake.
Wellington Management Group LLP and its affiliated entities have filed an amended passive investment disclosure (SCHEDULE 13G/A) regarding their beneficial ownership in Option Care Health, Inc. (OPCH). The filing indicates that Wellington beneficially owns 9,860,546 common shares, representing 6.6% ownership by most entities and 6.2% by Wellington Management Company LLP. This includes shared voting power over 8,670,373 shares for three of the entities and 8,618,238 shares for Wellington Management Company LLP.
A director proposes selling 6,492 stock-award shares in Option Care Health (OPCH).
Option Care Health, Inc. director Robert C. Pate has filed a notice to sell 6,492 common shares, valued at approximately $207,750, with an anticipated sale date of November 10, 2026. These shares were acquired as stock awards in May 2026. The filing indicates 149,799,704 shares outstanding for the company.
132,753 Option Care Health, Inc. $OPCH Shares Bought by Villere ST Denis J & Co. LLC
Villere ST Denis J & Co. LLC increased its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 17.0% during the third quarter, acquiring an additional 132,753 shares, bringing their total holdings to 913,012 shares valued at approximately $20.5 million. Despite this insider buying, analysts have a cautious outlook, with a consensus "Hold" rating and an average price target of $29.48. Option Care Health reported quarterly EPS of $0.49, matching estimates, and revenue of $1.49 billion, slightly exceeding forecasts with a 4.1% year-over-year growth.
Revenue rose 4.1% at Option Care Health (OPCH), while quarterly profit grew faster.
Option Care Health (OPCH) reported a 4.1% increase in third-quarter 2026 revenue to $1,493.5 million and a 10.8% rise in net income to $57.4 million, driven by strong growth in acute therapies. Despite a decline in the chronic inflammatory disease portfolio, the company's nine-month operating cash flow also significantly improved to $286.2 million. The company is in the process of being acquired by an investor group for $32.05 per share, with the deal expected to close in the first half of 2027, which will result in its privatization.
ARGA Investment Management LP Buys 89,979 Shares of Option Care Health, Inc. $OPCH
ARGA Investment Management LP has acquired 89,979 shares of Option Care Health, Inc. (NASDAQ:OPCH), a new position valued at approximately $2.02 million, representing 0.06% of the company. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 98.05% of the stock. Analyst sentiment remains largely neutral, with a consensus "Hold" rating and an average price target of $29.48.
Option Care Health (NASDAQ:OPCH) posts better-than-expected sales in Q3 2026
Option Care Health (NASDAQ:OPCH) reported better-than-expected revenue of $1.49 billion in Q3 2026, exceeding Wall Street estimates by 1.2% with a 4.1% year-on-year increase. The company's non-GAAP profit of $0.49 per share was in line with analyst consensus, while adjusted EBITDA also beat estimates. Despite a decent five-year revenue growth, future projections suggest a deceleration, and the company's operating margin remains mediocre, with EPS growth driven by stock buybacks rather than increased operational efficiency.
OPCH Stock Alert: Halper Sadeh LLC is Investigating Whether Option Care Health, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Option Care Health, Inc. (NASDAQ: OPCH) to CD&R, McKesson Corporation for $32.05 per share. The investigation focuses on whether Option Care Health and its board of directors violated federal securities laws or breached their fiduciary duties by failing to obtain the best possible price for shareholders, ensure a fair sales process, and disclose all material information. Halper Sadeh LLC is seeking increased consideration, additional disclosures, or other relief for shareholders.
BlackRock’s Option Care Health (OPCH) stake includes sole voting power over 19.1M shares.
BlackRock, Inc. reported a 13.1% beneficial ownership stake in Option Care Health, Inc. (OPCH) as of September 30, 2026, totaling 19,587,246 shares. The report specifies that BlackRock holds sole voting power over 19,143,612 shares and sole dispositive power over all 19,587,246 shares, with no shared voting or dispositive power. This Schedule 13G/A filing indicates a passive investment, not intended to influence control of the issuer.
Leeward Investments LLC MA Acquires 142,007 Shares of Option Care Health, Inc. $OPCH
Leeward Investments LLC MA increased its stake in Option Care Health (NASDAQ:OPCH) by 20.1% in the third quarter, acquiring an additional 142,007 shares to now own 848,059 shares valued at approximately $19.1 million. The company reported strong quarterly results, with revenue of $1.44 billion and EPS of $0.45, both exceeding analyst estimates. Despite positive earnings, analyst sentiment remains cautious, with a consensus "Hold" rating and an average price target of $29.48, below the recent trading price of $31.22.
Option Care Health, Inc. Estimates – NASDAQ:OPCH
This article provides an overview of Option Care Health, Inc. (NASDAQ: OPCH) financial data and analyst estimates available on TradingView. It highlights where users can explore reported financial data, compare actual results with estimates, and visualize trends over time across income statements, balance sheets, and cash flow statements. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
Option Care Health, Inc. (OPCH) Stock Forecasts
Argus has issued a research report on Option Care Health Inc (OPCH), a provider of home and alternate-site infusion services. The report, dated October 21, 2026, includes a rating and an earnings estimate, with the current price at $31.29. The full report offers detailed insights for those who upgrade to a premium service.
Top 3 Health Care Stocks That May Fall Off A Cliff In October
This article identifies three healthcare stocks—Option Care Health (OPCH), Pacira Biosciences (PCRX), and HealthStream (HSTM)—that appear overbought based on their high Relative Strength Index (RSI) values. All three companies have seen significant stock gains in the past month, despite recent analyst downgrades or initiations at a "Hold" rating. The author suggests these stocks could be flashing a warning to investors who rely on momentum in their trading decisions.
Option Care Health, Inc. $OPCH Shares Purchased by Fort Washington Investment Advisors Inc. OH
Fort Washington Investment Advisors Inc. OH increased its stake in Option Care Health (NASDAQ:OPCH) by 5.1% in the third quarter, bringing its total holdings to 1.42 million shares valued at approximately $32.0 million. This comes as Option Care Health reported strong Q3 earnings, beating estimates with $0.45 EPS and a 1.9% year-over-year revenue increase to $1.44 billion, and issued promising fiscal 2026 EPS guidance. Despite institutional ownership of 98.05%, analyst sentiment remains cautious with an average "Hold" rating.
Option Care Health (NASDAQ:OPCH): A Quality Investing Stock With Durable Growth and Strong Cash Generation
Option Care Health (NASDAQ:OPCH) is highlighted as a quality investing stock due to its durable growth and strong cash generation, according to a "Caviar Cruise" quality screen. The company, which provides home and alternate-site infusion services, exhibits consistent revenue and EBIT growth, high returns on invested capital, and manageable leverage. While future growth is expected to decelerate, its robust free cash flow and reasonable valuation make it an attractive candidate for long-term buy-and-hold investors.
Option Care Health Stock: 8 Straight Green Days, Up 38%
Option Care Health (OPCH) stock has seen significant gains, closing higher for eight consecutive sessions, accumulating a 38.3% increase and adding $1.3 billion to its market value. This surge largely outpaces the S&P 500's performance over the same period. Despite this impressive stock performance, the company's fundamentals show mixed results with revenue growth and operating margins below the S&P 500 Health Care median, though its trailing earnings multiple is lower.
OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, has announced an investigation into Option Care Health, Inc. (OPCH) for potential breaches of fiduciary duty by its directors and management. The firm encourages shareholders who have suffered a loss to participate in the investigation by contacting SBS for a free discussion of their rights. This investigation aims to determine if Option Care's board fulfilled its fiduciary responsibilities to its shareholders.
OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Option Care Health, Inc. (OPCH) for potential breaches of fiduciary duty by its directors and management. The firm is encouraging shareholders who have suffered losses to participate in the investigation. SBS specializes in securities class action lawsuits and shareholder rights litigation, advocating for investors globally.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Option Care Health, Inc. (NASDAQ: OPCH)
Monteverde & Associates PC, a class action law firm, has initiated an investigation into Option Care Health, Inc. (NASDAQ: OPCH) regarding its proposed sale to an investor group including affiliates of Clayton, Dubilier & Rice, LLC and McKesson Corporation. Shareholders are expected to receive $32.05 in cash per share, and the firm is investigating whether this represents a fair deal. The firm, headquartered in New York City, encourages shareholders with concerns to contact them for additional information.
Monteverde & Associates investigates Option Car...
Monteverde & Associates PC is investigating the proposed sale of Option Care Health, Inc. to an investor group for $32.05 per share in cash. The firm is evaluating the fairness of this price to shareholders and encourages those with concerns to seek legal advice. This comes amidst a positive market snapshot for US health stocks, as reported by Pluang.
A 7-Day Winning Streak Has Option Care Health Stock Up 38%
Option Care Health (OPCH) stock has seen a significant 7-day winning streak, gaining 38.2% and adding $1.3 billion to its market value, now at $4.8 billion. This surge, which far outpaced the S&P 500's 2.1% gain over the same period, puts the stock 15.1% below its 52-week high. Despite this impressive run, the company's fundamentals present a mixed picture with revenue growth and operating margins below the S&P 500 Health Care median, though its trailing P/E multiple is also below the median.
Option Care Health Stock: 6 Straight Green Days, Up 38%
Option Care Health (OPCH) stock has experienced a significant surge, rising 38.1% over six consecutive trading days, adding approximately $1.3 billion to its market value. This impressive performance contrasts sharply with the broader market, as the S&P 500 gained only 1.5% during the same period. While the stock's fundamentals show mixed signals with below-median revenue growth and operating margin, it trades at a lower P/E multiple compared to the sector median.
UBS Downgrades Option Care Health to Neutral From Buy, Price Target is $32.05
UBS has downgraded Option Care Health (OPCH) from a "Buy" to a "Neutral" rating, setting a new price target of $32.05. This adjustment was announced on October 9, 2026, by MT Newswires. The article also provides recent news and financial updates for Option Care Health, including earnings reports and previous analyst rating changes.
Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Option Care Health, Inc. (NasdaqGS: OPCH) to CD&R, McKesson Corporation for $32.05 per share in cash. Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and KSF are looking into whether this price and the process leading to it are adequate, suggesting the consideration might undervalue the company. Shareholders who believe the transaction undervalues the company or wish to discuss legal rights are encouraged to contact KSF.
OPCH Stock Alert: Halper Sadeh LLC is Investigating Whether Option Care Health, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Option Care Health, Inc. (NASDAQ: OPCH) to CD&R, McKesson Corporation for $32.05 per share. The firm is examining whether Option Care and its board of directors failed to secure the best possible price for shareholders, conduct a fair sales process, or disclose all material information. Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options.
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Several top Wall Street analysts have revised their ratings on key stocks, with a notable downgrade for Option Care Health Inc (NASDAQ: OPCH). Barrington Research moved Option Care Health from Outperform to Market Perform. Other companies facing downgrades include PJT Partners Inc (NYSE: PJT), Caribou Biosciences Inc (NASDAQ: CRBU), and Ambev SA (NYSE: ABEV), reflecting changing outlooks from Keefe, Bruyette & Woods, Leerink Partners, and B of A Securities, respectively.
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
CD&R and McKesson are set to acquire Option Care Health, an at-home infusion therapy provider, for approximately $5.8 billion including debt. CD&R will take a majority stake of 51%, while McKesson will invest about $1.4 billion for a 49% minority interest. Shares of Option Care Health surged 33% in premarket trading following the announcement.
McKesson, CD&R to acquire Option Care Health for $32.05 per share
McKesson Corporation and CD&R have announced a definitive agreement to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion. CD&R will hold a 51% majority interest, while McKesson will invest $1.4 billion for a 49% minority stake. Option Care Health will continue to operate as a separate entity under its existing management, and its stock will be delisted from Nasdaq upon the transaction's expected closing in the first half of 2027.
Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread
Option Care Health (NASDAQ: OPCH) has agreed to be acquired by Clayton Dubilier & Rice and McKesson Corp. (NYSE: MCK) for $32.05 per share in cash, valuing the company at approximately $5.8 billion. Despite the deal, shares are currently trading at $31.05, creating a $1 gap. The deal, which offers a 37% premium over Option Care's previous close, is expected to finalize in the first half of 2027, with McKesson eventually having the option to buy out CD&R's stake.
Option Care Health Soars 33% on $5.8 Billion Buyout by CD&R and McKesson: “A Great Outcome”
Option Care Health shares surged 33% after private equity firm CD&R and McKesson agreed to acquire the company for $32.05 per share in cash, valuing it at approximately $5.8 billion including debt. This represents a 37% premium to the previous day's close, with CD&R taking a 51% stake and McKesson investing $1.4 billion for 49%. The deal, expected to close in the first half of 2027 pending shareholder and regulatory approvals, offers a "great outcome" for existing stockholders, though upside for new buyers is limited due to the offer price being close to the current stock price.
Option Care Health surges 22% on report of $5 billion takeover by McKesson, CD&R
Option Care Health's shares surged 22% in after-hours trading after a Financial Times report indicated advanced talks for a $5 billion takeover by healthcare giant McKesson and private equity firm Clayton Dubilier & Rice (CD&R). Under the proposed terms, CD&R would hold a 51% controlling stake, with McKesson taking 49% and retaining a future right to purchase CD&R's stake. The deal could be finalized as early as Tuesday, valuing Option Care Health, including debt, at over $5 billion.
OPCH Stock Soars 22% After-Hours On $5B McKesson Buyout Talks
Option Care Health (OPCH) shares surged 22% after-hours following reports of a potential $5 billion buyout by McKesson (MCK) and private equity firm Clayton Dubilier & Rice. The deal, which could be finalized as early as Tuesday, would see CD&R owning 51% through a joint venture and McKesson 49%, with McKesson retaining a future purchase option. This acquisition would integrate Option Care's extensive medical infusion services with McKesson's existing drug distribution and oncology operations.
Option Care Health (OPCH) Draws Fresh Home Care Attention, Is It Still 20% Undervalued?
Option Care Health (OPCH) is gaining attention due to its home and alternate site infusion business, which could benefit from the shift of complex treatments to lower-cost home settings. While its share price has rebounded 8.41% over 90 days, it's down 29.25% year-to-date. Analysts believe it's 20.2% undervalued with a fair value of $28.58, driven by growth in infusion therapies and partnerships, but a discounted cash flow model suggests it might be overvalued at $22.81, estimating its future cash flow value at $18.15.
Option Care Health, Inc. (OPCH) Stock forecasts
Argus has raised its target price for Option Care Health, Inc. (OPCH) to $23.00. Option Care Health is a provider of home and alternate-site infusion services, offering treatments for various conditions including bleeding disorders, neurological disorders, and chronic inflammatory disorders. The report also lists the current price of OPCH at $23.07.
3 Healthcare Stocks with Warning Signs
This article identifies three healthcare stocks—Option Care Health (OPCH), Illumina (ILMN), and Merck (MRK)—that StockStory advises investors to approach with caution despite the healthcare industry's recent strong performance. The warnings are based on issues such as slowing sales growth, stagnant free cash flow, negative returns on capital, underwhelming revenue performance, and increasing expenses relative to revenue for these companies. The article suggests readers review detailed reports for a full understanding of these concerns.
Technical Reactions to OPCH Trends in Macro Strategies
This article from Stock Traders Daily discusses technical reactions to Option Care Health Inc. (NASDAQ: OPCH) trends, highlighting a stable neutral reading in shorter horizons that could indicate an easing of a long-term weak bias. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis. The analysis also points to an exceptional 73.3:1 risk-reward setup targeting a significant gain with minimal risk.
UBS reiterates Buy on Option Care Health stock on execution focus
UBS has reiterated a Buy rating and a $39.00 price target for Option Care Health (NASDAQ:OPCH), noting the company's consistent execution focus, strong performance in acute, immunoglobulin, and neurology portfolios, and expansion in chronic inflammatory disease. Despite a recent downgrade from Deutsche Bank due to growth concerns, InvestingPro data suggests the stock is undervalued, reinforcing UBS's positive outlook as the company explores tuck-in M&A opportunities and benefits from new therapies.
Option Care Health, Inc. (OPCH) Stock Analysis: Strong Buy Ratings and a 17.63% Upside Potential
Option Care Health, Inc. (OPCH) is a significant player in home and alternate site infusion services with a market cap of $3.64 billion. The company, currently trading at $24.30, has a positive outlook from analysts, with an average target price of $28.58 indicating a 17.63% upside potential. Despite not paying dividends, its strong free cash flow and strategic focus on growing healthcare demands position it as an attractive investment for growth-oriented investors.
Squarepoint Ops LLC Raises Stock Holdings in Option Care Health, Inc. $OPCH
Squarepoint Ops LLC significantly increased its stake in Option Care Health (NASDAQ:OPCH) during the second quarter, adding 304,376 shares to own a total of 434,408 shares valued at $9.1 million. This increase comes as Option Care Health exceeded quarterly earnings expectations with $0.45 adjusted EPS and $1.44 billion in revenue. Despite mixed analyst sentiment and some downgrades, a significant portion of the stock remains owned by hedge funds and institutional investors.
Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Rating of "Hold" by Brokerages
Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus "Hold" rating from fourteen brokerages, with an average 12-month price target of $29.92. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.45 EPS and $1.44 billion in revenue. Institutional investors hold a significant 98.05% of the company's outstanding shares.
Paralel Advisors LLC Purchases New Stake in Option Care Health, Inc. $OPCH
Paralel Advisors LLC has acquired a new stake in Option Care Health, Inc. (NASDAQ:OPCH), purchasing 85,835 shares valued at approximately $1.8 million in the second quarter. This move is part of broader institutional investor activity, with 98.05% of the company's stock owned by institutional investors and hedge funds. Despite mixed analyst ratings, Option Care Health exceeded quarterly earnings expectations, reporting $0.45 EPS and $1.44 billion in revenue.
Raiffeisen Bank International AG Purchases 120,000 Shares of Option Care Health, Inc. $OPCH
Raiffeisen Bank International AG significantly increased its stake in Option Care Health, Inc. by purchasing an additional 120,000 shares, bringing their total ownership to 250,000 shares valued at approximately $5.33 million. This move comes as Option Care Health has shown strong earnings, beating analysts' expectations, while its stock trades below its 52-week high. Analysts currently have a consensus "Hold" rating for the company with an average price target of $29.92.
Option Care Health Market Sentiment
This article provides an overview of market sentiment for Option Care Health (OPCH), detailing analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts, a 11.2% short float, and a bullish options flow with a 0.22 Put/Call ratio. The piece also lists recent analyst actions with their ratings, price targets, and changes.
Senior Health, Home Health & Hospice Stocks Q2 Results: Benchmarking Option Care Health (NASDAQ:OPCH)
This article analyzes Q2 earnings for senior health, home health, and hospice stocks, highlighting Option Care Health (OPCH) and its peers. Option Care Health reported strong Q2 results with revenues up 1.9% year-on-year, exceeding expectations. The broader industry faces challenges from labor costs and regulatory uncertainty but is poised for growth due to an aging population and increasing demand for in-home care.
Option Care Health to Participate in Upcoming Investor Conferences
Option Care Health announced that its CEO, John Rademacher, and CFO, Meenal Sethna, will participate in two upcoming investor conferences: the Morgan Stanley 24th Annual Global Healthcare Conference and the Deutsche Bank 2026 Healthcare Summit. The company, which is the nation's largest independent provider of home and alternate site infusion services, will make webcast links and presentation materials available on its investor relations website.
Two New York healthcare conferences will include Option Care Health’s CEO and CFO.
Option Care Health (OPCH) announced that its CEO, John Rademacher, and CFO, Meenal Sethna, will participate in two upcoming healthcare investor conferences in New York City in mid-September 2026. The company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, and the Deutsche Bank 2026 Healthcare Summit on September 16, 2026. Webcast links and presentation materials will be available on Option Care Health's investor relations website.
Bank of New York Mellon Corp Invests $19.60 Million in Option Care Health, Inc. $OPCH
Bank of New York Mellon Corp has acquired a new stake of 934,655 shares, valued at approximately $19.6 million, in Option Care Health, Inc. This investment represents about 0.62% of the company, with institutional investors now holding 98.05% of OPCH stock. Option Care Health recently surpassed quarterly earnings expectations, reporting $0.45 in adjusted EPS and $1.44 billion in revenue.
Wellington Management Group LLP Has $247.08 Million Holdings in Option Care Health, Inc. $OPCH
Wellington Management Group LLP decreased its stake in Option Care Health, Inc. by 1% in the second quarter but still retains a significant holding of 11.78 million shares valued at approximately $247.1 million, representing 7.87% of the company. Institutional ownership of Option Care Health is very high at 98.05%, with a mixed analyst sentiment leading to a consensus "Hold" rating and an average price target of $29.92. The company reported strong Q2 earnings, exceeding revenue and EPS estimates, with shares opening at $23.90, below their 52-week high.
Option Care Health, Inc. (OPCH) Stock Analysis: Navigating Growth with a 19% Upside Potential
Option Care Health, Inc. (OPCH) is a key player in home and alternate site infusion services, with a market capitalization of $3.59 billion and a potential upside of 19.37% based on an average price target of $28.58. The company shows operational efficiency with a robust return on equity of 16.00% and positive analyst sentiment, including eight buy ratings. Technical analysis suggests short-term bullish momentum, positioning OPCH to capitalize on the evolving home-based care sector.
Option Care Health (NASDAQ:OPCH): A Quality Stock with Durable Growth and Cash Flow
Option Care Health (NASDAQ:OPCH) is highlighted as a quality stock demonstrating durable growth and strong cash flow, passing a demanding "Caviar Cruise" screen. The company shows healthy revenue and EBIT growth, high return on invested capital, and robust profit quality with strong free cash flow generation. While financial health presents minor caveats, the stock trades at an attractive valuation for a quality-oriented strategy.